Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alterity Therapeutics Ltd ADR (NQ: ATHE )

2.450 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alterity Therapeutics Ltd ADR

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Appendix 4C – Q1 FY24 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
New Patent Covers Over 150 Novel Compounds 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
Presentations Highlight New Data on Diagnostic Accuracy and Novel Biomarkers of Disease Severity in Multiple System Atrophy 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
Wearable sensor parameters correlate strongly with clinical scales of motor impairment 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.